Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

Innate Pharma Reports Third Quarter 2026 Business and Financial Update

November 05, 2026

Performance

52-Week Range 47.2% below 52-week high

1.430

1.1752W Low 2.7152W High

1 Week 3.4% below 1-week high

1.321W Low 1.481W High

Innate Pharma S.A. - American Depositary Shares (IPHA) traded between $1.17 and $2.71 over the past 52 weeks and last traded at $1.43, 47.2% below its 52-week high. Over the past week it ranged between $1.32 and $1.48.

Past 12 Months

-2.1%

-10.1%

-19.9%

+4.4%

-21.4%

1W -$0.03

1M -$0.16

3M -$0.35

6M +$0.06

YTD -$0.39

1Y -$0.39

IPHA was -21.4% over the past year, +4.4% over six months, -21.4% year to date, -2.1% in the last week.

12 Months vs Market

IPHA

-21.4%

DIA

+8.7%

SPY

+9.0%

QQQ

+5.6%

IWM

+12.0%

Over the past 12 months IPHA returned -21.4% versus DIA (Dow) +8.7%, SPY (S&P 500) +9.0%, QQQ (Nasdaq 100) +5.6% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 0.03× 3-mo avg

Today 3,963 3-mo avg 158.2K

28.9K

24.0K

158.2K

112.6K

YTD

76.5K

111.6K

IPHA most recently traded 3,963 shares against a 3-month average daily volume of 158.2K.

More News

Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

October 27, 2026

Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference

October 21, 2026

Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update

October 20, 2026

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript ↗

September 17, 2026

Via The Motley Fool

Innate Pharma Q2 Earnings Call Highlights ↗

September 17, 2026

Innate Pharma Reports First Half 2026 Business Update and Financial Results

September 17, 2026

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

September 16, 2026

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

September 10, 2026

Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 02, 2026

Innate Pharma Secures €30M, Extends Cash Runway Into 2028 ↗

August 14, 2026

Innate Pharma Announces Conference Call and Webcast

August 14, 2026

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

Unusual volume stocks are being observed in Wednesday's session. ↗

August 12, 2026

Via Chartmill

The trading volume of these stocks is deviating from the norm in today's session. ↗

August 11, 2026

Via Chartmill

August 10, 2026

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

August 10, 2026

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference

July 23, 2026

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

July 21, 2026

Outcome of Innate Pharma’s 2026 Annual General Meeting

May 22, 2026

Innate Pharma to participate in the Jefferies Global Healthcare Conference

May 19, 2026

Innate Pharma Q1 Earnings Call Highlights ↗

May 13, 2026

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

May 13, 2026

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

May 12, 2026

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

May 06, 2026